Loading
A phase 1/2 trial of Paclitaxel / nab-paclitaxel in head and neck squamous cell carcinoma, run by Suzhou Junde Biotechnology Co., Ltd, active and no longer recruiting.
Study of TL117 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma is a phase 1/2 interventional study registered as NCT04843098 by Suzhou Junde Biotechnology Co., Ltd, with 108 participants planned, started 2021-05-26 and due to reach its primary completion in 2024-11-20. Interventions recorded: TL117, Paclitaxel. Conditions listed: Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Paclitaxel / nab-paclitaxel, Head and neck squamous cell carcinoma, Cytotoxic chemotherapy.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Paclitaxel / nab-paclitaxel, Head and neck squamous cell carcinoma, Cytotoxic chemotherapy.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma, Cytotoxic chemotherapy.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma.